now_approved_logo_mob

DARZALEX FASPRO® + VRd is FDA-approved   for a new indication

NCCN RECOMMENDATIONS

Daratumumab-containing regimens are recommended as treatment options by the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)*†‡

NCCN Guidelines® recommendations in newly diagnosed multiple myeloma

NCCN Guidelines preferred regimen for non-transplant candidates‡

DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1) primary therapy

NCCN Guidelines other recommended regimen for non-transplant candidates‡
DVMP: daratumumab (D), bortezomib (V), melphalan (M), and prednisone (P)(Category 1) primary therapy
NCCN Guidelines useful in certain circumstances for transplant candidates‡

DVTd: daratumumab (D), bortezomib (V), thalidomide (T), and dexamethasone (d) (Category 2A) primary therapy

NCCN Guidelines recommendations in relapsed or refractory multiple myeloma

NCCN Guidelines preferred regimens for early relapses (1-3 prior therapies)‡

DRd: daratumumab (D), lenalidomide (R), and dexamethasone (d) (Category 1)

DVd: daratumumab (D), bortezomib (V), and dexamethasone (d) (Category 1)

DKd: daratumumab (D), carfilzomib (K), and dexamethasone (d) (Category 1)

After 1 prior therapy including lenalidomide and a PI DPd: daratumumab (D), pomalidomide (P), and dexamethasone (d)§ (Category 1)

NCCN Guidelines useful in certain circumstances‡

After at least 3 prior therapies including a PI and an immunomodulatory agent or are double refractory to a PI and an immunomodulatory agent

Daratumumab (Category 2A)
PI=proteasome inhibitor.
*Daratumumab includes both daratumumab (DARZALEX®) for intravenous infusion and daratumumab and hyaluronidase-fihj (DARZALEX FASPRO®) for subcutaneous injection. Daratumumab and hyaluronidase-fihj for subcutaneous injection has different dosing and administration instructions compared to daratumumab for intravenous infusion.
†See NCCN.org for definitions of NCCN Categories of Preference and NCCN Categories of Evidence and Consensus.
‡Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.2.2024. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 2, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
§DARZALEX FASPRO® + Pd is FDA-approved in patients who have received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor (PI). DARZALEX® + Pd is FDA-approved in patients who have received ≥2 prior lines of therapy including lenalidomide and a PI.1,2
DARZALEX® and DARZALEX FASPRO® studied in wide range of clinical trials for multiple myeloma
Discover clinical data

References:

  1. DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.